Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 15/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.58 |
| ▸ | PREP | P48147 | 1/20 | 0.56 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bradykinin SCHEMBL7949679 | 0.95 | BDKRB2 (0.67) | BDKRB2OPRD1OPRM1 | |
| Bradykinin SCHEMBL7949684 | 0.95 | BDKRB2 (0.67) | BDKRB2OPRD1OPRM1 | |
| SCHEMBL17887567 | 0.93 | BDKRB2 (0.64) | BDKRB2OPRD1OPRM1 | |
| SCHEMBL29973237 | 0.93 | BDKRB2 (0.64) | BDKRB2OPRD1OPRM1 | |
| SCHEMBL30672572 | 0.92 | BDKRB2 (0.72) | BDKRB2OPRD1PREPOPRM1 | |
| SCHEMBL29973203 | 0.91 | BDKRB2 (0.67) | BDKRB2OPRD1OPRM1 | |
| SCHEMBL11169796 | 0.91 | BDKRB2 (0.67) | BDKRB2OPRD1OPRM1 | |
| SCHEMBL29599233 | 0.91 | BDKRB2 (0.74) | BDKRB2PREPMRGPRX2 | |
| SCHEMBL9796839 | 0.90 | BDKRB2 (0.65) | BDKRB2OPRD1OPRM1 | |
| SCHEMBL9796830 | 0.90 | BDKRB2 (0.65) | BDKRB2OPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144842-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS | TEMPLE OTORONGO LLC (US) | 2026-05-28 | — | — | US | claimed |
| US-11723945-B2 | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions | TEMPLE OTORONGO LLC (US) | 2023-08-15 | — | — | US | claimed |
| US-20260144842-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS | TEMPLE OTORONGO LLC (US) | 2026-05-28 | — | — | US | disclosed |
| US-11723945-B2 | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions | TEMPLE OTORONGO LLC (US) | 2023-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144842-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS | OPRK1, TPH1, HTR3C | BDKRB2 102/4885OPRD1 18/4885PREP 311/4885 |
| US-11723945-B2 | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions | TPH1, TPH2, SYMPK | BDKRB2 101/4885OPRD1 62/4885PREP 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.